- Chairman 꽁 머니 카지노 Jeong-jin re-elected as inside director at 25th regular shareholders' meeting
- Chairman 꽁 머니 카지노 Jeong-jin's health declines during business activities, but "recovering" after vocal cord surgery
[by Ji, Yong Jun] 꽁 머니 카지노 Chairman Seo Jung-jin has been reappointed for a two-year term, extended until March 2027.
At the regular shareholders' meeting held on the morning of March 25 at Songdo Convensia in Yeonsu District, Incheon, 꽁 머니 카지노 approved the motion to reappoint Chairman Seo Jung-jin as executive director. Seo's reappointment was approved by more than half of the voting rights of shareholders present, as well as by over a quarter of the total number of issued shares. The total number of shares represented at the meeting was 124,391,297, accounting for 60.67% of the total issued shares.
Seo was unable to attend the shareholders' meeting on this occasion due to personal reasons. "Chairman Seo's health recently deteriorated during business activities, and he is currently in recovery after surgery," said Seo Jin-seok, CEO of 꽁 머니 카지노.
Seo has demonstrated decisive leadership by addressing major pending issues during his previous term. Notably, he successfully completed the long-awaited merger of 꽁 머니 카지노 and 꽁 머니 카지노 Healthcare in just nine months following his return. This achievement is seen as laying the groundwork for 꽁 머니 카지노 to become a ‘global big pharma’ by acquiring a strong research and development (R&D) foundation and a global sales network.
Additionally, ‘Remsima (infliximab),’ a treatment for autoimmune diseases, surpassed KRW 1 trillion (approximately USD 682.6 million) in global sales last year, becoming Korea’s first ‘global blockbuster treatment.’ Furthermore, ‘Zymfentra (marketed in Europe as Remsima SC),’ a subcutaneous injection (SC) formulation of Remsima, was approved as a ‘novel drug’ by the U.S. Food and Drug Administration (FDA), positioning 꽁 머니 카지노 among leading new drug development companies. These accomplishments were achieved during Seo’s two-year term.